Research programme: hepatitis C virus protease inhibitors - InterMune

Drug Profile

Research programme: hepatitis C virus protease inhibitors - InterMune

Alternative Names: ITMN A; ITMN-5489; Second-generation HCV protease inhibitors - InterMune

Latest Information Update: 13 Feb 2012

Price : $50

At a glance

  • Originator Array BioPharma; InterMune
  • Developer InterMune; Roche
  • Class Small molecules
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 30 Jun 2011 Discontinued - Preclinical for Hepatitis C in USA (PO)
  • 13 Apr 2010 Preclinical development is ongoing in USA
  • 25 Apr 2009 Preclinical pharmacodynamics and pharmacokinetics data presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top